论文部分内容阅读
目的探讨曲美他嗪对冠状动脉慢性完全闭塞病变患者经皮冠状动脉介入治疗(PCI)术后心功能的影响。方法经冠状动脉造影确诊冠状动脉慢性完全闭塞病变患者90例,其中43例行PCI术,术后分为两组:A组23例,B组20例;未行PCI术47例,分为两组:C组25例,D组22例。A组、C组曲美他嗪口服,20mg,3次/d;B组、D组不服用曲美他嗪。4组均给予冠心病常规治疗。治疗跟踪观察12个月,其中A、B、C组各有1例、D组有2例死亡,剔除。比较4组治疗12个月前后超声心动图变化。结果A、B和C组治疗前后心功能均有明显改善,各组心功能超声学参数治疗后与治疗前比较差异有统计学意义(P<0.05);A组治疗后的心功能较B组治疗后的心功能改善更明显,A组治疗后心功能超声学参数与B组治疗后比较差异有统计学意义(P<0.05)。结论曲美他嗪能进一步改善冠状动脉慢性完全闭塞病变患者PCI术后的心功能。
Objective To investigate the effect of trimetazidine on cardiac function in patients with chronic total occlusion of coronary artery undergoing percutaneous coronary intervention (PCI). Methods Totally 90 patients with chronic total occlusion of coronary artery were diagnosed by coronary angiography. Among them, 43 patients underwent PCI. There were 23 patients in group A and 20 patients in group B. There were 47 patients without PCI, Group: C group 25 cases, D group 22 cases. Group A, group C trimetazidine oral, 20mg, 3 times / d; group B, group D did not take trimetazidine. 4 groups were given routine treatment of coronary heart disease. Treatment followed up for 12 months, of which 1 in each of A, B and C groups and 2 in D group died. Echocardiographic changes were compared between the 4 groups before and 12 months after treatment. Results The cardiac function of group A, B and C before and after treatment were significantly improved, and the difference of cardiac function after treatment between the two groups was statistically significant (P <0.05). After treatment, the cardiac function of group A was significantly lower than that of group B After treatment, the improvement of cardiac function was more obvious. The ultrasonic parameters of cardiac function after treatment in group A were significantly different from those in group B after treatment (P <0.05). Conclusion Trimetazidine can further improve the cardiac function in patients with chronic total occlusion of coronary artery after PCI.